Search results
Author(s):
Anjali T Owens
Added:
7 months ago
Navigate the rapidly evolving treatment landscape for hypertrophic cardiomyopathy with Dr Anjali Tiku Owens, a renowned expert in inherited cardiovascular diseases and advanced heart failure.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, explores both established and emerging therapeutic approaches for obstructive and non…
View more
Author(s):
Sara Saberi
Added:
7 months ago
Master the diagnostic complexities of hypertrophic cardiomyopathy (HCM) with Dr Sara Saberi, a leading expert in inherited cardiovascular diseases.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, provides essential insights into the nuanced approach required for accurate HCM diagnosis and risk stratification.Dr Saberi…
View more
Author(s):
Andrew Wang
Added:
6 months ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive…
View more
Author(s):
Gregory Lewis
Added:
7 months ago
HFSA 25 - Aficamten improves excercise capacity compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy in a prespecified analysis of the MAPLE-HCM study.Dr Gregory Lewis joins us to discuss findings from a prespecified cardiopulmonary exercise testing analysis of the MAPLE-HCM trial, which reveals divergent effects between aficamten and metoprolol on exercise performance…
View more
Author(s):
Joost Daemen
,
Nicolas M Van Mieghem
Added:
1 year ago
Keep up to date with the top trials from AHA 24!CLEAR-SYNERGYSELECT-CABGSUMMITYELLOW IIIInternational Aortic Stenosis RegistryAMPLATZER IDEVALOR HCMWatch our full AHA 24 coverage in our Late-Breaking and Featured Science Collection.
View more
Author(s):
Ahmad Masri
Added:
7 months ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in…
View more
Author(s):
Dipti Itchhaporia
Added:
1 year ago
ACC 2025 - In this succinct video, Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute & University of California, CA, US) outlines the key late-breaking trials from the conference that are expected to have an impact on clinical practice.Trials covered in detail include:FRESH-UPAPI-CATALIGN-ARPROTECT-TAVIRecorded on-site at ACC in Chicago, 2025.Support: This is an independent interview…
View more
Author(s):
Harriette Van Spall
,
Mark Petrie
Added:
2 years ago
HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.00:24 - STEP HFpEF Programme: Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF & Semaglutide therapy and diuretic use in obesity-related HFpEF02:20 - EMPACT-MI: The effect of…
View more
Author(s):
Marat Fudim
Added:
12 months ago
In this short interview, Dr Marat Fudim offers a preview of his upcoming manuscript, set to appear in the Sleep Disordered Breathing in Heart Failure special focus collection in Cardiac Failure Review. He discusses the evolving role of home sleep testing in diagnosing sleep apnea in patients with heart failure, addressing key considerations in clinical workflows and patient selection.Watch now to…
View more
Author(s):
Joost Daemen
,
Nicolas M Van Mieghem
Added:
1 year ago
Explore the cardiovascular breakthroughs shaping AHA 2024!Join renowned experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they preview the most impactful late-breaking studies poised to make waves at this year’s AHA Conference. Dive into their expert analysis and gain key insights into the studies that are set to drive the future of cardiovascular…
View more